Reduced abundance of Fusobacterium signifies cardiovascular benefits of sodium glucose cotransporter 2 inhibitor in type 2 diabetes: a single arm clinical trial
SGLT2i represents a superior initial therapeutic option for T2DM patients at risk of CVD. The cardiovascular benefits of SGLT2i may be attributed to shifts in the gut microbiota, particularly the reduced abundance of <i>Fusobacterium</i>.
Authors
- Xiaoxu Weng
- Qingsong Lin (ORCID: https://orcid.org/0000-0001-6082-8684)
- Shuhui Yang
- Xiao-shan Zeng
- Ying Xiao
- Canbin Zheng (ORCID: https://orcid.org/0000-0002-4560-8242)
- Jiankun Deng
- Kejun Hou (ORCID: https://orcid.org/0000-0003-1733-0068)
- Nie Lin
- Rui Zuo (ORCID: https://orcid.org/0000-0002-3564-1356)
- You Hu (ORCID: https://orcid.org/0009-0006-9823-1465)
- Zhaojie Ma
Institutions
- Shantou University (CN)
- Yue Bei People's Hospital (CN)
- Shantou Central Hospital (CN)
Publication Details
- Journal
- Frontiers in Pharmacology
- Published
- 2025-05-08
- DOI
- https://doi.org/10.3389/fphar.2025.1600464
- Citations
- 2
- Primary Topic
- Diabetes Treatment and Management
- Type
- article
- Field-Weighted Citation Impact
- 2.59
Funders
- National Natural Science Foundation of China
- Shantou Science and Technology Project